2014.... your thoughts and predictions, page-11

I think it's important to have realistic expectations, although obviously we can all dream! I'm looking for 15-20 cents in the next 6 months on full clinical data and further disclosure regarding Onyx combination trial, as I view a market cap of $100-150m as undemanding given what PAB has achieved to date. Looking at the performance of coys like AHZ, ADO and PSY and the renewed institutional interest in the biotech sector I believe that PAB is due for a re-rate, particularly once the RI shortfall is either placed or reaches its expiry after 3 months.

In the event of a licensing agreement for SM6 then yes the sky's the limit, the Bell Potter report had a $ value range of $100-200m from memory for SM6. If such a deal occurs, then think about the number of trials that can be funded as a result, SM6 is the tip of the iceberg! To me, that is the holy grail.

GLTA